Cargando…

FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma

Clear cell renal cell carcinoma (ccRCC), which is the most prevalent renal cell carcinoma subtype, has a poor prognosis. Emerging strategies for enhancing the immune response in ccRCC therapy are currently being investigated. Fibrinogen-like Protein 1(FGL1) is a novel mechanism that tumors may use t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Zheng, Cui, Bo, Huang, Xing, Feng, Hua-Yi, Wang, Tao, Wang, Han-Feng, Xuan, Yun-Dong, Li, Hong-Zhao, Ma, Xin, Huang, Yan, Zhang, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695555/
https://www.ncbi.nlm.nih.gov/pubmed/34956878
http://dx.doi.org/10.3389/fonc.2021.756843
_version_ 1784619605522644992
author Lv, Zheng
Cui, Bo
Huang, Xing
Feng, Hua-Yi
Wang, Tao
Wang, Han-Feng
Xuan, Yun-Dong
Li, Hong-Zhao
Ma, Xin
Huang, Yan
Zhang, Xu
author_facet Lv, Zheng
Cui, Bo
Huang, Xing
Feng, Hua-Yi
Wang, Tao
Wang, Han-Feng
Xuan, Yun-Dong
Li, Hong-Zhao
Ma, Xin
Huang, Yan
Zhang, Xu
author_sort Lv, Zheng
collection PubMed
description Clear cell renal cell carcinoma (ccRCC), which is the most prevalent renal cell carcinoma subtype, has a poor prognosis. Emerging strategies for enhancing the immune response in ccRCC therapy are currently being investigated. Fibrinogen-like Protein 1(FGL1) is a novel mechanism that tumors may use to evade the immune system by binding LAG-3 and negatively regulating T cells. In this study, we aimed at investigating the underlying mechanism of FGL1 in ccRCC, and its expression and prognostic value. We found that FGL1 was upregulated in tumor tissues and plasma specimens of ccRCC patients. High FGL1 expression predicted a poor prognosis for ccRCC patients. We also discovered that overexpression of FGL1 enhances RCC cell migration, invasion, and metastasis by activating the epithelial-to-mesenchymal transition (EMT). Consistent with these results, we identified a significant positive correlation between expression of FGL1 and EMT-related genes through tissue microarray analysis. Gene-expression analysis revealed that FGL1-deficient ccRCC cell lines had altered transcriptional output in inflammatory response, cell-cell signaling, negative regulation of T cell activation, and intracellular signal transduction. Depletion of FGL1 significantly inhibited tumor growth and lung metastasis in orthotopic xenograft mouse model. Infiltration of myeloid-derived CD11b+ and Ly6G+ immune cells in tumor microenvironment (TME) was strikingly decreased when FGL1 expression reduced. Therefore, increased FGL1 expression in ccRCC is positively correlated with poor prognosis. Mechanistically, FGL1 facilitates the EMT process and modulates TME, which promotes ccRCC progression and metastasis. Consequently, targeting FGL1 can potentially improve clinical outcome of ccRCC patients.
format Online
Article
Text
id pubmed-8695555
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86955552021-12-24 FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma Lv, Zheng Cui, Bo Huang, Xing Feng, Hua-Yi Wang, Tao Wang, Han-Feng Xuan, Yun-Dong Li, Hong-Zhao Ma, Xin Huang, Yan Zhang, Xu Front Oncol Oncology Clear cell renal cell carcinoma (ccRCC), which is the most prevalent renal cell carcinoma subtype, has a poor prognosis. Emerging strategies for enhancing the immune response in ccRCC therapy are currently being investigated. Fibrinogen-like Protein 1(FGL1) is a novel mechanism that tumors may use to evade the immune system by binding LAG-3 and negatively regulating T cells. In this study, we aimed at investigating the underlying mechanism of FGL1 in ccRCC, and its expression and prognostic value. We found that FGL1 was upregulated in tumor tissues and plasma specimens of ccRCC patients. High FGL1 expression predicted a poor prognosis for ccRCC patients. We also discovered that overexpression of FGL1 enhances RCC cell migration, invasion, and metastasis by activating the epithelial-to-mesenchymal transition (EMT). Consistent with these results, we identified a significant positive correlation between expression of FGL1 and EMT-related genes through tissue microarray analysis. Gene-expression analysis revealed that FGL1-deficient ccRCC cell lines had altered transcriptional output in inflammatory response, cell-cell signaling, negative regulation of T cell activation, and intracellular signal transduction. Depletion of FGL1 significantly inhibited tumor growth and lung metastasis in orthotopic xenograft mouse model. Infiltration of myeloid-derived CD11b+ and Ly6G+ immune cells in tumor microenvironment (TME) was strikingly decreased when FGL1 expression reduced. Therefore, increased FGL1 expression in ccRCC is positively correlated with poor prognosis. Mechanistically, FGL1 facilitates the EMT process and modulates TME, which promotes ccRCC progression and metastasis. Consequently, targeting FGL1 can potentially improve clinical outcome of ccRCC patients. Frontiers Media S.A. 2021-12-09 /pmc/articles/PMC8695555/ /pubmed/34956878 http://dx.doi.org/10.3389/fonc.2021.756843 Text en Copyright © 2021 Lv, Cui, Huang, Feng, Wang, Wang, Xuan, Li, Ma, Huang and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lv, Zheng
Cui, Bo
Huang, Xing
Feng, Hua-Yi
Wang, Tao
Wang, Han-Feng
Xuan, Yun-Dong
Li, Hong-Zhao
Ma, Xin
Huang, Yan
Zhang, Xu
FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma
title FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma
title_full FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma
title_fullStr FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma
title_full_unstemmed FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma
title_short FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma
title_sort fgl1 as a novel mediator and biomarker of malignant progression in clear cell renal cell carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695555/
https://www.ncbi.nlm.nih.gov/pubmed/34956878
http://dx.doi.org/10.3389/fonc.2021.756843
work_keys_str_mv AT lvzheng fgl1asanovelmediatorandbiomarkerofmalignantprogressioninclearcellrenalcellcarcinoma
AT cuibo fgl1asanovelmediatorandbiomarkerofmalignantprogressioninclearcellrenalcellcarcinoma
AT huangxing fgl1asanovelmediatorandbiomarkerofmalignantprogressioninclearcellrenalcellcarcinoma
AT fenghuayi fgl1asanovelmediatorandbiomarkerofmalignantprogressioninclearcellrenalcellcarcinoma
AT wangtao fgl1asanovelmediatorandbiomarkerofmalignantprogressioninclearcellrenalcellcarcinoma
AT wanghanfeng fgl1asanovelmediatorandbiomarkerofmalignantprogressioninclearcellrenalcellcarcinoma
AT xuanyundong fgl1asanovelmediatorandbiomarkerofmalignantprogressioninclearcellrenalcellcarcinoma
AT lihongzhao fgl1asanovelmediatorandbiomarkerofmalignantprogressioninclearcellrenalcellcarcinoma
AT maxin fgl1asanovelmediatorandbiomarkerofmalignantprogressioninclearcellrenalcellcarcinoma
AT huangyan fgl1asanovelmediatorandbiomarkerofmalignantprogressioninclearcellrenalcellcarcinoma
AT zhangxu fgl1asanovelmediatorandbiomarkerofmalignantprogressioninclearcellrenalcellcarcinoma